Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Trial to Evaluate the Efficacy and Safety of KarXT when Dosed in Conjunction with Background Antipsychotic Therapy for the Treatment of Psychosis in Patients with Schizophrenia who have an Inadequate Response to Current Standard of Care Therapies

Next Previous
Trial Profile

A Phase 2 Trial to Evaluate the Efficacy and Safety of KarXT when Dosed in Conjunction with Background Antipsychotic Therapy for the Treatment of Psychosis in Patients with Schizophrenia who have an Inadequate Response to Current Standard of Care Therapies

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 07 Aug 2020 New trial record
  • 05 Aug 2020 According to a Karuna Therapeutics media release, data evaluating this study is intended to support a supplemental NDA filing assuming the successful development of KarXT as a monotherapy for the treatment of adults with schizophrenia. The Company plans to initiate this trial following the initiation of the Phase 3 trials within the EMERGENT program.
  • 05 Aug 2020 According to a Karuna Therapeutics media release, the company was previously planned to initiate a phase Ib trial assessing potential Drug-Drug Interactions with a selection of currently marketed antipsychotics in healthy volunteers, but based on multiple considerations, including the evaluation of existing preclinical and clinical data supporting the potential of KarXT to augment traditional antipsychotic drugs, the Company will move forward directly to initiate a Phase 2 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top